Clinical Trial Update: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and tolerability study of NC762 in patients with advanced or metastatic solid tumors has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• NC762

Snippet

Sponsor: NextCure, Inc. | Conditions: Advanced or Metastatic Solid Tumors, Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-04-22